A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

被引：0
|
作者：
William Schelman
Sherry Morgan-Meadows
Howard Bailey
Kyle Holen
James P. Thomas
Jens Eickhoff
Heidi Brandon
Kate Oliver
Dona Alberti
George Wilding
机构：
[1] University of Wisconsin Paul P. Carbone Comprehensive Cancer Center,
[2] Southern Cancer Center,undefined
[3] The Ohio State University Comprehensive Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Gemcitabine; Patupilone; Chemotherapy; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：727 / 733
页数：6
相关论文
共 50 条
  • [41] Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors
    Brian A. Costello
    Mitesh J. Borad
    Yingwei Qi
    George P. Kim
    Donald W. Northfelt
    Charles Erlichman
    Steven R. Alberts
    Investigational New Drugs, 2014, 32 : 710 - 716
  • [42] Pemetrexed/gemcitabine/cisplatin: Phase I trial in patients with solid tumors
    Bolling, C
    Lubbing, C
    Graefe, T
    Mack, S
    Von Scheel, J
    Muller-Hagen, S
    Blatter, J
    Depenbrock, H
    Ohnmacht, U
    Hanauske, AR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 218S - 218S
  • [43] Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors
    Costello, Brian A.
    Borad, Mitesh J.
    Qi, Yingwei
    Kim, George P.
    Northfelt, Donald W.
    Erlichman, Charles
    Alberts, Steven R.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 710 - 716
  • [44] Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
    Chan, Emily
    Chiorean, E. Gabriela
    O'Dwyer, Peter J.
    Gabrail, Nashat Y.
    Alcindor, Thierry
    Potvin, Diane
    Chao, Richard
    Hurwitz, Herbert
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (02) : 355 - 364
  • [45] Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
    Emily Chan
    E. Gabriela Chiorean
    Peter J. O’Dwyer
    Nashat Y. Gabrail
    Thierry Alcindor
    Diane Potvin
    Richard Chao
    Herbert Hurwitz
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 355 - 364
  • [46] Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
    Wells A. Messersmith
    Antonio Jimeno
    David Ettinger
    Dan Laheru
    Julie Brahmer
    Dina Lansey
    Yasmin Khan
    Ross C. Donehower
    Yusri Elsayed
    Peter Zannikos
    Manuel Hidalgo
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 181 - 188
  • [47] Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
    Messersmith, Wells A.
    Jimeno, Antonio
    Ettinger, David
    Laheru, Dan
    Brahmer, Julie
    Lansey, Dina
    Khan, Yasmin
    Donehower, Ross C.
    Elsayed, Yusri
    Zannikos, Peter
    Hidalgo, Manuel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 181 - 188
  • [48] Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.
    Karim, Nagla Fawzy Abdel
    Ahmad, Imran
    Gaber, Ola
    Eldessouki, Ihab
    Olowokure, Olugbenga Olanrele
    Farooq, Maria
    Morris, John Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors
    Bommakanti, Satya V.
    Dudek, Arkadiusz Z.
    Khatri, Amit
    Kirstein, Mark N.
    Gada, Purvi D.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (06): : 597 - 602
  • [50] A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma
    Leibrandt, Ryan
    Frankel, Paul Henry
    Beumer, Jan Hendrik
    Takebe, Naoko
    Yin, Ming
    Emamekhoo, Hamid
    Lara, Primo Lucky N.
    Gore, Steven
    Parikh, Mamta
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345